Allergy Therapeutics (GB:AGY) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Allergy Therapeutics has announced promising interim results from its Phase I/IIa trial of VLP Peanut, a potential new treatment for peanut allergies. The data shows a significant reduction in skin sensitivity among patients and suggests the treatment can effectively boost immune response while reducing allergic reactions. This progress marks a significant step forward in developing a novel therapy for peanut allergy, with plans to continue dose escalation in future trials.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
